Literature DB >> 12706357

Effects of low dose tamoxifen on normal breast tissue from premenopausal women.

G R de Lima1, G Facina, J Y Shida, M B C Chein, P Tanaka, R C Dardes, V C Jordan, L H Gebrim.   

Abstract

The aim of this study was to determine the effects of low doses of tamoxifen (5 and 10mg/day) for 50 days compared with the standard dose (20 mg/day) on breast biomarkers measured in normal breast tissue from premenopausal patients. A randomised double-blind study was performed using tissue from 56 premenopausal women with a diagnosis of fibroadenoma of the breast. Excisional biopsy was performed on the 50th day of therapy. Normal breast tissue samples were collected during surgery. The patients were divided in groups: A (placebo, n=11); group B (5 mg, n=16), group C (10 mg, n=14) and group D (20 mg, n=15). In this cross-sectional study, differences in the expression of Oestrogen Receptor alpha (ERalpha), Progesterone Receptor (PR), Ki-67, apoptotic bodies and mitotic index between the different groups after treatment can be seen on the normal breast tissue. We believe that a lower dose of tamoxifen could reduce the side-effects associated with treatment without affecting its chemopreventive activity in the breast.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12706357     DOI: 10.1016/s0959-8049(02)00530-0

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  17 in total

1.  Effect of Bazedoxifene and Conjugated Estrogen (Duavee) on Breast Cancer Risk Biomarkers in High-Risk Women: A Pilot Study.

Authors:  Carol J Fabian; Lauren Nye; Kandy R Powers; Jennifer L Nydegger; Amy L Kreutzjans; Teresa A Phillips; Trina Metheny; Onalisa Winblad; Carola M Zalles; Christy R Hagan; Merit L Goodman; Byron J Gajewski; Devin C Koestler; Prabhakar Chalise; Bruce F Kimler
Journal:  Cancer Prev Res (Phila)       Date:  2019-08-16

2.  Addressing barriers to uptake of breast cancer chemoprevention for patients and providers.

Authors:  Katherine D Crew
Journal:  Am Soc Clin Oncol Educ Book       Date:  2015

3.  Clinical Trial of Acolbifene in Premenopausal Women at High Risk for Breast Cancer.

Authors:  Carol J Fabian; Bruce F Kimler; Carola M Zalles; Teresa A Phillips; Trina Metheny; Brian K Petroff; Thomas C Havighurst; KyungMann Kim; Howard H Bailey; Brandy M Heckman-Stoddard
Journal:  Cancer Prev Res (Phila)       Date:  2015-09-21

4.  Randomized Phase IIB Trial of the Lignan Secoisolariciresinol Diglucoside in Premenopausal Women at Increased Risk for Development of Breast Cancer.

Authors:  Carol J Fabian; Seema A Khan; Judy E Garber; William C Dooley; Lisa D Yee; Jennifer R Klemp; Jennifer L Nydegger; Kandy R Powers; Amy L Kreutzjans; Carola M Zalles; Trina Metheny; Teresa A Phillips; Jinxiang Hu; Devin C Koestler; Prabhakar Chalise; Nanda Kumar Yellapu; Cheryl Jernigan; Brian K Petroff; Stephen D Hursting; Bruce F Kimler
Journal:  Cancer Prev Res (Phila)       Date:  2020-04-20

5.  Tamoxifen downregulates ets oncogene family members ETV4 and ETV5 in benign breast tissue: implications for durable risk reduction.

Authors:  David Euhus; Dawei Bu; Xian-Jin Xie; Venetia Sarode; Raheela Ashfaq; Kelly Hunt; Weiya Xia; Joyce O'Shaughnessy; Michael Grant; Banu Arun; William Dooley; Alexander Miller; David Flockhart; Cheryl Lewis
Journal:  Cancer Prev Res (Phila)       Date:  2011-07-21

6.  Somatic expression of PyMT or activated ErbB2 induces estrogen-independent mammary tumorigenesis.

Authors:  Michael J Toneff; Zhijun Du; Jie Dong; Jian Huang; Parisa Sinai; James Forman; Susan Hilsenbeck; Rachel Schiff; Shixia Huang; Yi Li
Journal:  Neoplasia       Date:  2010-09       Impact factor: 5.715

Review 7.  Minireview: Progesterone Regulation of Proliferation in the Normal Human Breast and in Breast Cancer: A Tale of Two Scenarios?

Authors:  Heidi N Hilton; J Dinny Graham; Christine L Clarke
Journal:  Mol Endocrinol       Date:  2015-08-12

8.  Tamoxifen citrate encapsulated sustained release liposomes: preparation and evaluation of physicochemical properties.

Authors:  Buddhadev Layek; Biswajit Mukherjee
Journal:  Sci Pharm       Date:  2010-07-12

9.  Activation of the mTOR pathway by low levels of xenoestrogens in breast epithelial cells from high-risk women.

Authors:  William H Goodson; Maria Gloria Luciani; S Aejaz Sayeed; Ian M Jaffee; Dan H Moore; Shanaz H Dairkee
Journal:  Carcinogenesis       Date:  2011-09-01       Impact factor: 4.944

10.  Development, characterization, and in vitro evaluation of tamoxifen microemulsions.

Authors:  E Monteagudo; Y Gándola; L González; C Bregni; A M Carlucci
Journal:  J Drug Deliv       Date:  2012-01-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.